As previously reported, RBC Capital analyst Gregory Renza upgraded Verrica Pharmaceuticals to Outperform from Sector Perform with a price target of $11, up from $4. In its recent meetings with the company management, Verrica Pharmaceuticals expressed confidence in regulatory proceedings for VP-102 in molluscum contagiosum following successful tech transfer, the recently disclosed site inspections, and NDA resubmission, the analyst tells investors in a research note. The firm now has "increased confidence" in the drug’s regulatory path forward and a more granular view on market dynamics and strategy supported by data from physicians and payers.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRCA:
- Verrica upgraded to Outperform from Sector Perform at RBC Capital
- Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
- Verrica Pharmaceuticals resubmits NDA for VP-102 in molluscum contagiosum
- Verrica Pharmaceuticals announces technology transfer to Piramal Pharma
- Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
